Well here is the answer to your ridiculous questions you

New Post Public Reply Private Reply Replies (2) Message Board
Thoth kickask #2809
352
Well here is the answer to your ridiculous questions you sent me.

kickask questions in italic || my answers in bold

After going through the 10-k filed yesterday, I think it is time for me to tap out. I think this is going to be great long term. I just think it is going to be at least two years before this gets any traction.

2 years before we get traction? What the hell are you smoking? It is 420 after all so you must be on something really medicinal saying 2 years before we get traction.


Based on PR and 10-k, not sure if they will get another company store up and running in 2017. They need minimum $700k to open a new store and don't know if there is any indication they can get that.

Where in the hell did you come up with this madness? We just released a PR in Jan. stating QIC, $78 billion alternative investment fund, is going to pay for the entire build out of our new restaurant in Tanforan. QIC is offering us $1.4 mil in tenant allowances and your saying the store only cost 700k? That means they are giving us double the amount in tenant allowances and your not impressed by that? Give me a freaking break because the CEO just discussed all of this in mondays PR that you said you READ. Apparently your lying about reading the PR so why in the hell would I believe you have 2 mil shares or read a comprehensive 10k?

I was hopeful with Jillian and Tia but not a whole lot to describe there involvement other than some PR

They weren't signed until 2017. What type of question is that?

Also, disappointed to not see Kaufman and Gay listed in the 10-k anywhere. They are referred to as officers in PR's but not in the 10-k. Unfortunately, I think the market has beat me to distribution, so it will be very difficult to bring down my share count without further price erosion


Gay and Kaufman not being in the 10k? They havent been in any of our filings. All it takes is a simple email or phone call to the company in order to confirm those 2 individuals are still on board $GIGL.

(FWIW, this is the exact same bullshit remark dsix made on ihub. I posted a screenshot of my email correspondence with the CEO proving Kaufman and Gay are still onboard && in turn correcting that loser (DSIX aka TKFRESH) on the ihub board. In FACT, It's what made Dsix change his name from TKFresh to DSix on the ihub forum. Coincidence that you raise the same exact same concern? I think not. After all Dsix, or friends of his, you did say you were going to stalk my username around the internet, right?)


In other words, your concerns made ZERO sense. If you hold 2 mil shares of $GIGL and your selling because of the reasons above, then you are out of your got damn mind. Want to send me bullshit, let the board read it and have their own opinion on your ridiculous message.

Giggles And Hugs Inc (GIGL) Stock Research Links

GIGL Board Company Profile Buy Rating Time & Sales News Filings Financials
mA2IsJPWGJ-how-do-you-feel-about-gigl-bulls.gif
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 20

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading